Yogita Rochlani
Advanced Heart Failure and Transplant Cardiology · Bronx, NYNPI 1427498401
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,594 of the $6,616 with a category attached, or 69.4%. 20 manufacturers reported payments, led by Abbott at 52.4% of the total. Reporting peaked in 2019 at $2,777 and has fallen 69.3% since, to $852 in 2025. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in NY, where the typical reported total is $5,971.
Across 112 payments — averaging $59.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Medtronic$848
- Ancora Heart, Inc.$504
- Alnylam Pharmaceuticals Inc.$323
- AstraZeneca$233
- Cvrx, Inc.$170
- plus $1K from 14 others
Across 4 payments — averaging $4994.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$20K
What the payments were for
- Travel & lodging$1,77027%
- Food & beverage$4,59469%
- Education$2524%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 38 | $3,466 |
| Medtronic | 4 | $848 |
| Ancora Heart, Inc. | 1 | $504 |
| Alnylam Pharmaceuticals Inc. | 10 | $323 |
| AstraZeneca | 6 | $233 |
| Cvrx, Inc. | 5 | $170 |
| Merck | 9 | $163 |
| Novartis | 8 | $151 |
| Pfizer | 8 | $137 |
| Astellas Pharma US Inc | 1 | $100 |
| Actelion Pharmaceuticals US, Inc. | 3 | $81 |
| Abiomed | 2 | $79 |
| E.r. Squibb & Sons, L.L.C. | 4 | $71 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $62 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $61 |
| Scpharmaceuticals Inc. | 3 | $61 |
| Bayer | 1 | $31 |
| Lantheus Medical Imaging, Inc. | 1 | $27 |
| Akcea Therapeutics, Inc. | 1 | $26 |
| Bristol Myers Squibb | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,616 in reported general payments places this provider in the 50th percentile of 106 advanced heart failure and transplant cardiology providers in New York.
See all advanced heart failure and transplant cardiology providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 12 | $588,555 |
| EntrestoSacubitril/Valsartan | 110 | $117,553 |
| JardianceEmpagliflozin | 62 | $61,207 |
| EliquisApixaban | 55 | $60,821 |
| FarxigaDapagliflozin Propanediol | 21 | $32,679 |
| Sildenafil Citrate | 12 | $8,641 |
| Metoprolol Succinate | 122 | $2,170 |
| Mycophenolate Mofetil | 11 | $1,756 |
| Atorvastatin Calcium | 67 | $840 |
| Eplerenone | 18 | $725 |
| Hydralazine Hcl | 33 | $672 |
| Spironolactone | 110 | $640 |
| Torsemide | 37 | $605 |
| Ezetimibe | 19 | $555 |
| Amiodarone Hcl | 21 | $301 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $137 | $649,37667 claims |
| NovartisEntresto | $151 | $117,553110 claims |
| AstraZenecaFarxiga | $233 | $32,67921 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 106 advanced heart failure and transplant cardiology providers in New York.
Other advanced heart failure and transplant cardiology in Bronx
- Johanna ContrerasNew York$534K
- Scott FeitellRochester$422K
- Sean PinneyNew York$305K
- Mathew MaurerNew York$249K
- Gregg LanierHawthorne$239K
- Michelle BloomMineola$166K
- Norbert MoskovitsBrooklyn$159K
- Stephen PanValhalla$159K
- Dor LotanNew York$158K
- Nir UrielNew York$125K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.